Expediting Antibody Discovery and Characterization with Flow Cytometry
Overview
eBook: Expediting Antibody Discovery and Characterization with Flow Cytometry
Advances in analytical techniques have increased the efficiency of therapeutic antibody discovery and facilitated rapid growth of the monoclonal antibody (mAb) market. FDA approved mAb therapeutics, include those for indicated for treatment of cancers and immune disorders, such as rheumatoid arthritis.
The current next generation mAbs utilize the following types of modifications to existing therapeutics, to improve characteristics such as potency or specificity:
- Engineered Fc regions
- Specificity adaptations, in the case of bi- and tri-specific antibodies
- Fragmented antibodies, for instance nanobodies
- Conjugated antibodies, such as antibody-drug conjugates
The iQue® Advanced Flow Cytometry Platform, with validated assays and reagent kits, provides a streamlined solution for high-throughput antibody screening and characterization.
Low volume samples are rapidly acquired from 96- or 384-well plates, then processed in the integrated iQue Forecyt® software, with auto-compensation and simple data analysis, to deliver fast, actionable results. Hence contributing towards the discovery and development of mAbs.
This eBook highlights some of the most recent advancements in the field of antibody discovery, covering a range of methods of antibody characterization and novel modalities.
- Document type: eBook
- Page count: 25
- Read time: 30 minutes
Key Takeaways
This eBook includes elaborations on the following news items:
- AI-Based Strategy Boosts High-Affinity Antibody Drug Discovery
- Anti-Tumor Activity Enhances When Immunomodulatory Antibodies Loosen Their Grip
- First-In-Class Immune Checkpoint Therapy Unlocks NK Cell Attack on Tumors
